ANA380: Final Phase I/II data

In a double-blind, placebo-controlled, dose-escalation, Chinese and Korean Phase I/II trial in 28 patients, 4 weeks of treatment with 60 mg or higher dose of ANA380 reduced viral load by >99.9%. Data ...